We study the proteins expressed by immune cells – those proteins circulating in human plasma – to discover novel therapeutics. Our motivation is to reverse disease pathology.

Our work is highly interdisciplinary and collaborative, and intersects the domains of epigenetics and gene expression modulation, proteomic discovery, and synthetic protein mimicry for biological applications.

Our process starts with nature-inspired molecular design, chemical synthesis, and finally, rigorous in vitro and in vivo testing for the intended medical use.

2008 – Dr. Barron invents antimicrobial “peptoid” structures.

2015 – MaxWell is founded and funded by Joshua McClure.

2016 – Dr. Barron and MaxWell team up.

2017 – Heterochronic Optimized Plasma Exchange (HOPE)

2018 – Gene expression modulation inventions